Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer

Overview of attention for article published in Frontiers in Public Health, January 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 1 X post from an account with 5,118 followers.

New Research: Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer: Background and objective Tislelizumab is a programmed… https://t.co/WtcmYWGRWg #PublicH

30 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.